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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comimbalances between trials conﬁrmed non-signiﬁcant differences between stent type
and stent thrombosis rates. The trend for a higher deﬁnite stent thrombosis rate in the
BES group was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60];
p¼0.16).
Conclusions: At 1-year follow-up the biodegradable polymer-coated BES has similar
stent thrombosis rates as the durable polymer-coated EES. However, incidence of
deﬁnite stent thrombosis is numerically higher in the BES group without reaching
statistical signiﬁcance. Longer follow-up is needed to determine the safety proﬁle of
biodegradable polymer-coated BES in real world clinical practice.Events at 1 years
EES BES
p-value(n¼2,530) (n¼3,412)
Deﬁnite Stent Thrombosis
All Stent Thrombosis 0.2% (5) 0.5% (17) 0.08
Early Stent Thrombosis 0.2% (4) 0.4% (13) 0.14
Late Stent Thrombosis 0.04% (1) 0.1% (4) 0.40
Deﬁnite or Probable Stent Thrombosis
All Stent Thrombosis 0.4% (10) 0.5% (18) 0.57
Early Stent Thrombosis 0.3% (8) 0.4% (13) 0.83
Late Stent Thrombosis 0.1% (2) 0.2% (5) 0.71TCT-645
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Background: Bioresorbable scaffolds (BVS) are a new treatment for coronary artery
disease with promising results in ﬁrst-in-man studies. As their use is extending in more
complex lesions and populations, several cases of BVS thrombosis have been re-
ported. We present optical coherence tomography ﬁndings from the culprit lesion of
patients with BVS thrombosis.
Methods: Up to 1/5/2014, 442 patients received BVS in our center. Among those, 14
patients that developed deﬁnite BVS thrombosis, according to the ARC criteria, were
readmitted to our cathlab. Eight of them were imaged by optical coherence tomog-
raphy (OCT) at the time of the event. OCT images were reviewed ofﬂine and the
presence of thrombus, underexpansion, neointimal hyperplasia >50%, incomplete
scaffold apposition, and scaffold discontinuity were assessed. The current status of
dual antiplatelet therapy at the time of the event was also recorded.
Results: Thrombus was visualized in 7/8 cases, underexpansion in 1/8, neointimal
hyperplasia >50% in 2/8, incomplete scaffold apposition in 4/8, and scaffold
discontinuity in 2/8 cases. In 3 cases, dual antiplatelet therapy had been discontinued
at the time of the event. A summary of the most prominent OCT ﬁndings is presented
in the Table.Case
Type/
timing Baseline OCT ﬁndings Prominent OCT ﬁndings at event
Dual
antiplatelet
therapy
1 Acute/
same day
Thrombus at proximal stent edge,
deriving from an adjacent
ﬁbroatheroma
Yes
2 Subacute/
2 days
Thrombus overlying extensive overlap
region (7.6mm)
Yes
3 Late/
40 days
Undersizing/residual
thrombus/plaque
prolapse
Incomplete scaffold apposition with
thrombus
Yes
4 Late/
4 months
Occlusive edge restenosis Yes
5 Late/
4 months
Uncovered struts at the carina of a
bifurcation treated with T-stenting
No
6 Late/
4 months
Scaffold fracture Thrombus overlying overlap region
with underexpansion/ scaffold
fracture
No
7 Late/
7 months
Incomplete scaffold apposition/
occlusive restenosis
Yes
8 Very late/
2 years
Optimal scaffold
expansion
Late scaffold discontinuity/
incomplete scaffold apposition
No
B188 JACC Vol 64/11/Suppl B j SeptemberConclusions: Discontinuation of antiplatelet therapy was identiﬁed in some patients
as a reason for BVS thrombosis, however, in the majority of the cases mechanical
factors were identiﬁed by OCT as a substrate. OCT can provide useful insights on the
pathomechanisms of this complication.
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Background: Incidence of late stent thrombosis (ST) is increasing due to the persistent
risk of thrombosis after implantation. Most of the cases are treated with percutaneous
coronary intervention (PCI). PCI of late-ST with additional stent implantation has been
associated with worse outcomes. Intravascular ultrasound (IVUS) imaging is able to
assess the pathological causes of late-ST and guide the best treatment. The objectives of
this study are to describe the IVUS ﬁndings of late-ST and compare outcomes between
patients treated without and with additional stent implantation.
Methods: All patients with late-ST (>1 month) undergoing IVUS-guided PCI were
included in 7 Spanish institutions. The operators were left to decide the PCI treatment:
balloon angioplasty (POBA) vs. stent implantation. Four IVUS ﬁndings were
assessed: late incomplete stent apposition (LISA), aneurysm, stent underexpansion
and excessive neointimal proliferation.
Results: 117 patients were included (54.4% drug-eluting stents). The median time
after implantation was 3.5 years. ST was presented as ST-elevation myocardial
infarction in 99 (84.1%) patients. Additional stent implantation was used in 54 patients
(46.2%). Prior to intervention, there were no differences in LISA (71.4% vs. 63.0%;
p¼0.33), aneurysm (11.1% vs. 11.1%; p¼1.0), underexpansion (31.7% vs. 18.5%;
p¼0.10) or excessive neointimal proliferation (11.1% vs. 22.2%; p¼0.10) between
patients treated with POBA vs. additional stent implantation. After PCI, persistent
LISA was observed in 25.4% vs. 51.9% of patients (p¼0.01), respectively. Persistent
underexpansion was observed in 6.3% and 14.8% (p¼0.05). Follow-up was obtained
at 2.0 years. Cardiac death was observed in 3.4% vs. 5.8% of patients treated without
and with additional stent (p¼0.55). Deﬁnite or probable re-thrombosis was observed
in 1.7% vs. 7.7% (p¼0.13), respectively.
Conclusions: The most frequent IVUS ﬁndings of late-ST are LISA and under-
expansion. POBA seems to improve these IVUS-ﬁndings with respect to additional
stent implantation. IVUS-guided treatment of deﬁnite ST is associated with favorable
outcomes independently of the use of additional stent implantation.
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Background: Stent thrombosis (ST) has been described as a rare event in current
drug-eluting stent (DES) era; however, its occurrence has been associated with high
morbimortality, including fatality rates up to 50%. Previous studies have shown ST
could be increased in complex subsets; however, the incidence and predictors of ST
after DES overtime are still no fully understood
Methods: A total of 5,408 pts with >8,000 coronary lesions undergoing routine or
emergency PCI were prospectively (and consecutively) enrolled in the DESIRE
(Drug-Eluting Stent In the REal World) registry at single institution between May/
2002 and May/2012 (enrollment ongoing). By protocol, clinical follow-up was per-
formed at 1 and 6 months, and yearly up to 12 years post-index procedure (97%).
Stent thrombosis (ST) was deﬁned according to the propositions of the Academic
Research Consortium.
Results:Mean age was 65 years, 32% had diabetes, and 16% had clinical presentation
of recent myocardial infarction (MI) (< 30 days). Overall, patients were treated with
approximately 8,500 DES and angiographic success was high (>99%) despite rela-
tively high complexity in the majority of lesions (67% type B2/C). Up to 12 years
(median 4.9 years) FU, cumulative incidence of ST was 2.4%, given that 95.1% of
patients were ST-free at 10 years (Kaplan-Meier survival curve). Of the 113 ST re-
ported, 13% occured up to 30 days, 55% were deﬁnite ST (ARC), and >60% occured
12 months. Independent predictors of ST are shown in the Table.13–17, 2014 j TCT Abstracts/Stents - Drug-Eluting: Stent Thrombosis
Predictors of Overall ST HR 95% CI p value
Recent MI up to 72 hours 2.66 1.52-4.66 0.001
Recent MI >72 hours 1.89 1.08-3.29 0.03
Multiple DES implanted 1.89 1.28-2.80 0.002
SVG 2.21 1.29-3.78 0.004
Residual stenosis (QCA analysis) 1.03 1.00-1.05 0.03
Predictors of Deﬁnite ST
Recent MI up to 72 hours 3.68 1.87-7.23 <0.001
Multiple DES implanted 2.24 1.30-3.86 0.004
SVG 2.62 1.32-5.22 0.006
Predictors of Early ST (up to 30 days)
OR 95% CI p value
Diabetes 2.45 0.014
Recent MI up to 72 hours 3.65 <0.001
www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMConclusions: In this study, pts had relatively low cumulative incidence of ST (2.4%),
given that around 95% of patients were ST-free up to 12 yrs. Signiﬁcant predictors of
overall ST were recent MI, multiple stent implantation, SVG and stent under-
expansion; as for deﬁnite ST only, predictors were recent MI, multiple stent im-
plantation and SVG; considering early ST occuring up to 30 days, predictors were
diabetes and recent MI.Coronary Lesions - In-stent Restenosis
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Background: Stent fracture is related to restenosis after drug-eluting stent (DES) im-
plantation. As percutaneous coronary intervention (PCI) cases for complex lesions
increased, those for stent fracture-related restenosis also increased. However, the optimal
PCI strategy for such restenosis remains unclear. We compared the results of PCI with
plain old balloon angioplasty (POBA), paclitaxel-coated balloon (PCB), and DES (siro-
limus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent, everolimus-eluting
stent, and biolimus-eluting stent) for restenosis with stent fracture after DES implantation.
Methods: From November 2002 to December 2012, 9357 patients with 15894 lesions
underwent DES implantation successfully. Of these, 12918 lesions were angio-
graphically followed up after 6 to 8 months (midterm f/u) and 9989 were followed up
at 12 months after midterm f/u. Stent fracture occurred in 576 (4.5%) of the 12918
lesions and restenosis with stent fracture occurred in 206 lesions. Restenosis with stent
fracture was deﬁned as a restenosis lesion within 5 mm from a stent fracture site. Of
the 206 lesions, target lesion revascularization by PCI with POBA, PCB, or DES was
performed on 124 lesions.
Results: Data are shown in the ﬁgure. At 2-year f/u, the cumulative incidence of re-
restenosis was signiﬁcantly lower after retreatment with DES than that with POBA
and PCB. In addition, late catch-up phenomenon was found after retreatment with
PCB.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoConclusions: Retreatment with DES could be an acceptable treatment for restenosis
with stent fracture after DES implantation.
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Background: Presence of stent fracture (SF) after sirolimus-eluting stent (SES) im-
plantation has reported to be associated with an increased risk of adverse events and
those are previously reported. But little is known about the outcomes after re-inter-
vention for SES restenosis lesion with SF.
Methods: From April 2007 to August 2011, total 2059 lesions implanted SES during
PCI at our hospital. Total 228 lesions, 11.1% had restenosis (deﬁned as %diameter
stenosis >50%) in follow-up angiogram until March 2013. Subjects of the study were
49 lesions 42 patients those implanted SES for denovo coronary artery stenosis and in-
stent restenosis with SF was documented in follow-up angiogram. SF was deﬁned as
complete or partial separation of the stent as assessed by plain ﬂuoroscopy. During the
target lesion revascularization procedure, 14 lesions implanted everolimus-eluting
stent (EES group), 20 lesions implanted sirolimus- and paclitaxel-eluting stent,
stainless steel stent with durable polymer (SS group). And also 15 lesions were dilated
with balloon angioplasty alone (POBA group). We compared the outcomes of
3 groups retrospectively.
Results: Baseline characteristics were similar. One-year cumulative incidence of
restenosis after repeat intervention those calculated by Kaplan-Meier methods were
EES group 22%, SS group 66% and POBA group 76%, respectively. EES group
signiﬁcantly reduced the cumulative incidence of restenosis after repeat intervention
(versus SS group; p¼0.0471 and POBA group; p¼0.0085).
Conclusions: For reduction in incidence of re-restenosis for the SES restenosis lesion
with SF during 1-year after repeat intervention, cobalt chromium EES implantations
were superior to stainless steel stent with durable polymer or balloon angioplasty
alone.
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Background: Stent fracture (SF) is an unresolved, clinically relevant issue, even in
the newer-generation drug-eluting stent era. The PROMUS Element platinum-chro-
mium everolimus-eluting stent (PtCr-EES; Boston Scientiﬁc, Natick, Massachusetts)
is designed to provide the improved fracture resistance, whereas the incidence and
clinical impact of SF after PtCr-EES implantation remains unclear. The aim of this
study was to assess the incidence and clinical impact of SF after PtCr-EES
implantation.
Methods: Between March 2012 and June 2013, a total of 676 patients with 839 le-
sions undergoing PtCr-EES implantation and follow-up angiography within 9 months
after index procedure were analyzed. SF was deﬁned as complete or partial separation
of the stent, as assessed by plain ﬂuoroscopy, intravascular ultrasound, or optical
coherence tomography during the follow-up. We assessed the rate of SF and the
cumulative incidence of clinically-driven target lesion revascularization and deﬁnite
stent thrombosis within 9 months.
Results: SF was observed in 12 of 839 lesions (1.4%) and 12 of 676 patients (1.7%).
Cumulative incidence of clinically-driven target lesion revascularization within 9
months was numerically higher in the SF group than that in the non-SF group (25.0%
versus 2.4%). Cumulative incidence of deﬁnite early and late stent thrombosis within
9-month was similar between the SF and non-SF groups (0.0% versus 0.2%).
Conclusions: SF after PtCr-EES occurs in 1.4% of lesions and appears to be asso-
ciated with clinically-driven target lesion revascularization.
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